Systemic administration of the HMGB1 fragment induces angiogenesis and reduces fibrosis by mobilizing BM-MSCs to the peri-infarction area, thereby providing a potential new approach for the treatment of ICM with CHF. This evidence concerns the gene HMGB1 and infarction.